@article{MTMT:34803210,
	title = {Ustekinumab in Crohn's disease: A three-year multicentre prospective study from Hungary - Assessing efficacy, drug sustainability, and safety},
	url = {https://m2.mtmt.hu/api/publication/34803210},
	author = {Barkai, L. J. and Gonczi, L. and Farkas, K. and Farkas, B. and Molnar, T. and Szamosi, T. and Schafer, E. and Golovics, P. and Juhasz, M. and Patai, A. and Vincze, Áron and Sarlós, Patrícia and Farkas, A. and Dubravcsik, Z. and Toth, T. G. and Miheller, P. and Lakatos, P. L. and Ilias, A.},
	journal-iso = {J CROHNS COLITIS},
	journal = {JOURNAL OF CROHNS & COLITIS},
	volume = {18},
	unique-id = {34803210},
	issn = {1873-9946},
	year = {2024},
	eissn = {1876-4479},
	pages = {I1249-I1249},
	orcid-numbers = {Vincze, Áron/0000-0003-2217-7686; Sarlós, Patrícia/0000-0002-5086-9455}
}

@article{MTMT:34509107,
	title = {Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab},
	url = {https://m2.mtmt.hu/api/publication/34509107},
	author = {Szemes, Kata and Borbásné Farkas, Kornélia and Sipos, Zoltán and Bor, Renáta and Fábián, Anna and Szepes, Zoltán and Farkas, Klaudia and Molnár, Tamás and Schafer, Eszter and Szamosi, Tamas and Salamon, Agnes and Vincze, Áron and Sarlós, Patrícia},
	doi = {10.3390/biomedicines12010158},
	journal-iso = {BIOMEDICINES},
	journal = {BIOMEDICINES},
	volume = {12},
	unique-id = {34509107},
	abstract = {Concomitant medications may alter the effect of biological therapy in inflammatory bowel disease. The aim was to investigate the effect of proton pump inhibitors on remission rates in patients with inflammatory bowel disease treated with the gut-selective vedolizumab. Patients from the Hungarian nationwide, multicenter vedolizumab cohort were selected for post hoc analysis. Primary outcomes were the assessment of clinical response and endoscopic and clinical remission at weeks 14 and 54. Secondary outcomes were the evaluation of the combined effect of concomitant steroid therapy and other factors, such as smoking, on remission. A total of 108 patients were identified with proton pump inhibitor data from 240 patients in the original cohort. Patients on steroids without proton pump inhibitors were more likely to have a clinical response at week 14 than patients on concomitant PPI (95% vs. 67%, p = 0.005). Non-smokers with IBD treated with VDZ were more likely to develop a clinical response at week 14 than smokers, particularly those not receiving PPI compared with patients on co-administered PPI therapy (81% vs. 53%, p = 0.041, and 92% vs. 74%, p = 0.029, respectively). We found that the use of PPIs in patients treated with VDZ may impair the achievement of response in certain subgroups. Unnecessary PPI prescriptions should be avoided.},
	year = {2024},
	eissn = {2227-9059},
	orcid-numbers = {Borbásné Farkas, Kornélia/0000-0002-5349-6527; Sipos, Zoltán/0000-0001-7845-8116; Bor, Renáta/0000-0001-9393-5240; Fábián, Anna/0000-0002-0824-7476; Szepes, Zoltán/0000-0002-9466-8719; Farkas, Klaudia/0000-0003-0599-182X; Molnár, Tamás/0000-0002-4913-7599; Vincze, Áron/0000-0003-2217-7686; Sarlós, Patrícia/0000-0002-5086-9455}
}

@article{MTMT:34434496,
	title = {Discharge protocol in acute pancreatitis: an international survey and cohort analysis},
	url = {https://m2.mtmt.hu/api/publication/34434496},
	author = {Nagy, Rita and Ocskay, Klementina and Sipos, Zoltán and Szentesi, Andrea Ildikó and Vincze, Áron and Czakó, László and Izbéki, Ferenc and Shirinskaya, Natalia V and Poluektov, Vladimir L and Zolotov, Alexandr N and Zhu, Yin and Xia, Liang and He, Wenhua and Sutton, Robert and Szatmary, Peter and Mukherjee, Rajarshi and Burridge, Isobel Saffron and Wauchope, Emma and Francisco, Elsa and Aparicio, David and Pinto, Bruno and Gomes, António and Nunes, Vitor and Tantau, Vasile Marcel and Sagau, Emanuela Denisa and Tantau, Alina Ioana and Suceveanu, Andra Iulia and Tocia, Cristina and Dumitru, Andrei and Pando, Elizabeth and Alberti, Piero and Cirera, Arturo and Molero, Xavier and Lee, Hong Sik and Jung, Min Kyu and Kim, Eui Joo and Lee, Sanghyub and Rebollo, María Lourdes Ruiz and Nistal, Reyes Busta and Santervas, Sandra Izquierdo and Lesko, Dusan and Soltes, Marek and Radonak, Jozef and Zatorski, Hubert and Małecka-Panas, Ewa and Fabisiak, Adam and Yaroslav, M Susak and Mykhailo, V Maksymenko and Olekcandr, A Tkachenko and Barauskas, Giedrius and Simanaitis, Vytautas and Ignatavicius, Povilas and Jinga, Mariana and Balaban, Vasile-Daniel and Patoni, Cristina and Gong, Liang and Song, Kai and Li, Yunlong and Gonçalves, T Cúrdia and Freitas, Marta and Macedo, Vítor and Vornhuelz, Marlies and Klauss, Sarah and Beyer, Georg and Koksal, Aydin Seref and Tozlu, Mukaddes and Eminler, Ahmet Tarik and Monclús, Nuria Torres and Comas, Eva Pijoan and Oballe, Juan Armando Rodriguez and Nawacki, Łukasz and Głuszek, Stanisław and Rama-Fernández, Alberto and Galego, Marco and de la Iglesia, Daniel and Aykut, Umut Emre and Duman, Deniz Güney and Aslan, Rahmi and Gherbon, Adriana and Deng, Lihui and Huang, Wei and Xia, Qing and Poropat, Goran and Radovan, Anja and Vranić, Luka and Ricci, Claudio and Ingaldi, Carlo and Casadei, Riccardo and Negoi, Ionut and Ciubotaru, Cezar and Iordache, Florin Mihail and Constantinescu, Gabriel and Sandru, Vasile and Altintas, Engin and Balci, Hatice Rizaoglu and Constantino, Júlio and Aveiro, Débora and Pereira, Jorge and Gunay, Suleyman and Misirlioglu Sucan, Seda and Dronov, Oleksiy and Kovalska, Inna and Bush, Nikhil and Rana, Surinder Singh and Chooklin, Serge and Chuklin, Serhii and Saizu, Ionut Adrian and Gheorghe, Cristian and Göltl, Philipp and Hirth, Michael and Mateescu, Radu Bogdan and Papuc, Geanina and Minkov, Georgi Angelov and Enchev, Emil Tihomirov and Mastrangelo, Laura and Jovine, Elio and Chen, Weiwei and Zhu, Quping and Gąsiorowska, Anita and Fabisiak, Natalia and Bezmarevic, Mihailo and Litvin, Andrey and Mottes, Martina Cattani and Choi, Eun Kwang and Bánovčin, Peter and Nosáková, Lenka and Kovacheva-Slavova, Mila Dimitrova and Kchaou, Ali and Tlili, Ahmed and Marino, Marco V and Kusnierz, Katarzyna and Mickevicius, Artautas and Hollenbach, Marcus and Molcan, Pavol and Ioannidis, Orestis and Tokarev, Mark Valerievich and Ince, Ali Tüzün and Semenenko, Ivan Albertovich and Galeev, Shamil and Ramírez-Maldonado, Elena and Sallinen, Ville and Pencik, Petr and Bajor, Judit and Sarlós, Patrícia and Hágendorn, Roland and Gódi, Szilárd and Szabó, Imre and Czimmer, József and Pár, Gabriella and Illés, Anita and Faluhelyi, Nándor and Kanizsai, Péter László and Nagy, Tamás and Mikó, Alexandra and Németh, Balázs and Hamvas, József and Bod, Barnabás and Varga, Márta and Török, Imola and Novák, János and Patai, Árpád and Sümegi, János and Góg, Csaba and Papp, Mária and Erőss, Bálint Mihály and Váncsa, Szilárd and Teutsch, Brigitta and Márta, Katalin and Hegyi, Péter Jenő and Tornai, Tamás and Lázár, Balázs and Hussein, Tamás and Tarján, Dorottya and Lipp, Mónika Bernadett and Kovács, Beáta and Urbán, Orsolya and Fürst, Emese Rita and Tari, Edina and Kocsis, Ibolya and Maurovich-Horvat, Pál and Tihanyi, Balázs and Eperjesi, Orsolya and Kormos, Zita and Deák, Pál Ákos and Párniczky, Andrea and Hegyi, Péter},
	doi = {10.1038/s41598-023-48480-z},
	journal-iso = {SCI REP},
	journal = {SCIENTIFIC REPORTS},
	volume = {13},
	unique-id = {34434496},
	issn = {2045-2322},
	abstract = {There are several overlapping clinical practice guidelines in acute pancreatitis (AP), however, none of them contains suggestions on patient discharge. The Hungarian Pancreatic Study Group (HPSG) has recently developed a laboratory data and symptom-based discharge protocol which needs to be validated. (1) A survey was conducted involving all members of the International Association of Pancreatology (IAP) to understand the characteristics of international discharge protocols. (2) We investigated the safety and effectiveness of the HPSG-discharge protocol. According to our international survey, 87.5% (49/56) of the centres had no discharge protocol. Patients discharged based on protocols have a significantly shorter median length of hospitalization (LOH) (7 (5;10) days vs. 8 (5;12) days) p < 0.001), and a lower rate of readmission due to recurrent AP episodes (p = 0.005). There was no difference in median discharge CRP level among the international cohorts (p = 0.586). HPSG-protocol resulted in the shortest LOH (6 (5;9) days) and highest median CRP (35.40 (13.78; 68.40) mg/l). Safety was confirmed by the low rate of readmittance (n = 35; 5%). Discharge protocol is necessary in AP. The discharge protocol used in this study is the first clinically proven protocol. Developing and testifying further protocols are needed to better standardize patients' care.},
	year = {2023},
	eissn = {2045-2322},
	orcid-numbers = {Nagy, Rita/0000-0002-2663-4912; Ocskay, Klementina/0000-0001-5848-2506; Sipos, Zoltán/0000-0001-7845-8116; Szentesi, Andrea Ildikó/0000-0003-2097-6927; Vincze, Áron/0000-0003-2217-7686; Czakó, László/0000-0002-6331-0802; Izbéki, Ferenc/0000-0001-7767-4319; Sarlós, Patrícia/0000-0002-5086-9455; Czimmer, József/0000-0001-7831-3523; Kanizsai, Péter László/0000-0001-7896-2857; Nagy, Tamás/0000-0001-5437-1411; Németh, Balázs/0000-0001-5338-7577; Papp, Mária/0000-0003-3662-4010; Erőss, Bálint Mihály/0000-0003-3658-8427; Váncsa, Szilárd/0000-0002-9347-8163; Teutsch, Brigitta/0000-0002-9530-7886; Márta, Katalin/0000-0002-2213-4865; Tari, Edina/0000-0002-8540-0614; Kocsis, Ibolya/0000-0003-3128-2832; Maurovich-Horvat, Pál/0000-0003-0885-736X; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:34196830,
	title = {CFTR p.F508del Mutation Carrier Status Is Not Associated With Biliary Acute Pancreatitis},
	url = {https://m2.mtmt.hu/api/publication/34196830},
	author = {Martonosi, Ágnes Rita and Németh, Balázs Csaba and Párniczky, Andrea and Vincze, Áron and Szentesi, Andrea Ildikó and Erőss, Bálint Mihály and Sahin-Tóth, Miklós and Hegyi, Péter and Hegyi, Eszter},
	doi = {10.1097/MPA.0000000000002241},
	journal-iso = {PANCREAS},
	journal = {PANCREAS},
	volume = {52},
	unique-id = {34196830},
	issn = {0885-3177},
	year = {2023},
	eissn = {1536-4828},
	pages = {e256-e257},
	orcid-numbers = {Martonosi, Ágnes Rita/0000-0001-6528-4671; Vincze, Áron/0000-0003-2217-7686; Szentesi, Andrea Ildikó/0000-0003-2097-6927; Erőss, Bálint Mihály/0000-0003-3658-8427; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:34072590,
	title = {Invalidity of Tokyo guidelines in acute biliary pancreatitis : A multicenter cohort analysis of 944 pancreatitis cases},
	url = {https://m2.mtmt.hu/api/publication/34072590},
	author = {Juhász, Márk Félix and Tóháti, Rebeka and Jászai, Viktória Adrienn and Molnár, Regina and Borbásné Farkas, Kornélia and Czakó, László and Vincze, Áron and Erőss, Bálint Mihály and Szentesi, Andrea Ildikó and Izbéki, Ferenc and Papp, Mária and Hegyi, Péter and Párniczky, Andrea},
	doi = {10.1002/ueg2.12402},
	journal-iso = {UEG JOURNAL},
	journal = {UNITED EUROPEAN GASTROENTEROLOGY JOURNAL},
	volume = {11},
	unique-id = {34072590},
	issn = {2050-6406},
	abstract = {There is a noteworthy overlap between the clinical picture of biliary acute pancreatitis (AP) and the 2018 Tokyo guidelines currently used for the diagnosis of cholangitis (AC) and cholecystitis (CC). This can lead to significant antibiotic and endoscopic retrograde cholangiopancreatography (ERCP) overuse.We aimed to assess the on-admission prevalence of AC/CC according to the 2018 Tokyo guidelines (TG18) in a cohort of biliary AP patients, and its association with antibiotic use, ERCP and clinically relevant endpoints.We conducted a secondary analysis of the Hungarian Pancreatic Study Group's prospective multicenter registry of 2195 AP cases. We grouped and compared biliary cases (n = 944) based on the on-admission fulfillment of definite AC/CC according to TG18. Aside from antibiotic use, we evaluated mortality, AC/CC/AP severity, ERCP performance and length of hospitalization. We also conducted a literature review discussing each criteria of the TG18 in the context of AP.27.8% of biliary AP cases fulfilled TG18 for both AC and CC, 22.5% for CC only and 20.8% for AC only. Antibiotic use was high (77.4%). About 2/3 of the AC/CC cases were mild, around 10% severe. Mortality was below 1% in mild and moderate AC/CC patients, but considerably higher in severe cases (12.8% and 21.2% in AC and CC). ERCP was performed in 89.3% of AC cases, common bile duct stones were found in 41.1%.Around 70% of biliary AP patients fulfilled the TG18 for AC/CC, associated with a high rate of antibiotic use. Mortality in presumed mild or moderate AC/CC is low. Each of the laboratory and clinical criteria are commonly fulfilled in biliary AP, single imaging findings are also unspecific-AP specific diagnostic criteria are needed, as the prevalence of AC/CC are likely greatly overestimated. Randomized trials testing antibiotic use are also warranted.},
	keywords = {MORTALITY; Antibiotic use; cholangitis; endoscopic retrograde cholangiopancreatography; cholecystitis; ERCP; STONES; Biliary acute pancreatitis; 2018 Tokyo guidelines},
	year = {2023},
	eissn = {2050-6414},
	pages = {767-774},
	orcid-numbers = {Molnár, Regina/0009-0009-7067-1647; Borbásné Farkas, Kornélia/0000-0002-5349-6527; Czakó, László/0000-0002-6331-0802; Vincze, Áron/0000-0003-2217-7686; Erőss, Bálint Mihály/0000-0003-3658-8427; Szentesi, Andrea Ildikó/0000-0003-2097-6927; Izbéki, Ferenc/0000-0001-7767-4319; Papp, Mária/0000-0003-3662-4010; Hegyi, Péter/0000-0003-0399-7259; Váncsa, Szilárd/0000-0002-9347-8163; Márta, Katalin/0000-0002-2213-4865; Nagy, Rita/0000-0002-2663-4912; Imrei, Marcell/0000-0003-0175-7462; Maurovich-Horvat, Pál/0000-0003-0885-736X; Doros, Attila/0000-0002-6496-9895; Zubek, László/0000-0003-0583-3290; Gál, János/0000-0001-9160-6478}
}

@article{MTMT:33864451,
	title = {Detailed characteristics of post-discharge mortality in acute pancreatitis},
	url = {https://m2.mtmt.hu/api/publication/33864451},
	author = {Turcsiné Czapári, Dóra and Váradi, Alex and Borbásné Farkas, Kornélia and Nyári, Gergely Róbert and Márta, Katalin and Váncsa, Szilárd and Nagy, Rita and Teutsch, Brigitta and Bunduc, Stefania and Erőss, Bálint Mihály and Czakó, László and Vincze, Áron and Izbéki, Ferenc and Papp, Mária and Merkely, Béla Péter and Szentesi, Andrea Ildikó and Hegyi, Péter},
	doi = {10.1053/j.gastro.2023.05.028},
	journal-iso = {GASTROENTEROLOGY},
	journal = {GASTROENTEROLOGY},
	volume = {165},
	unique-id = {33864451},
	issn = {0016-5085},
	abstract = {The in-hospital survival of patients suffering from acute pancreatitis (AP) is 95-98%. However, there is growing evidence that patients discharged after AP may be at risk of serious morbidity and mortality. Here, we aimed to investigate the risk, causes, and predictors of the most severe consequence of the post-AP period: mortality.2,613, well-characterized patients from twenty-five centers were collected and followed by the Hungarian Pancreatic Study Group between 2012 and 2021. A general and a hospital-based population was used as the control group.After an AP episode patients have an approximately three-fold higher incidence rate of mortality than the general population (0.0404vs.0.0130 person-years). First-year mortality after discharge was almost double than in-hospital mortality (5.5%vs.3.5%), with 3.0% occurring in the first 90-day period. Age, comorbidities, and severity were the most significant independent risk factors for death following AP. Furthermore, multivariate analysis identified creatinine, glucose, and pleural fluid on admission as independent risk factors associated with post-discharge mortality. In the first 90-day period, cardiac failure and AP-related sepsis were among the main causes of death following discharge, while cancer-related cachexia and non-AP-related infection were the key causes in the later phase.Almost as many patients in our cohort die in the first 90-day period after discharge as during their hospital stay. Evaluation of cardiovascular status, follow-up of local complications, and cachexia-preventing oncological care should be an essential part of post-AP patient care. Future study protocols in AP must include at least a 90-day follow-up period after discharge.},
	year = {2023},
	eissn = {1528-0012},
	pages = {682-695},
	orcid-numbers = {Váradi, Alex/0000-0001-8229-6340; Borbásné Farkas, Kornélia/0000-0002-5349-6527; Márta, Katalin/0000-0002-2213-4865; Váncsa, Szilárd/0000-0002-9347-8163; Nagy, Rita/0000-0002-2663-4912; Teutsch, Brigitta/0000-0002-9530-7886; Erőss, Bálint Mihály/0000-0003-3658-8427; Czakó, László/0000-0002-6331-0802; Vincze, Áron/0000-0003-2217-7686; Izbéki, Ferenc/0000-0001-7767-4319; Papp, Mária/0000-0003-3662-4010; Merkely, Béla Péter/0000-0001-6514-0723; Szentesi, Andrea Ildikó/0000-0003-2097-6927; Hegyi, Péter/0000-0003-0399-7259; Imrei, Marcell/0000-0003-0175-7462; Németh, Balázs/0000-0001-5338-7577; Tiszlavicz, László/0000-0003-1134-6587; Oláh, Orsolya/0000-0002-5731-4030; Vitális, Zsuzsanna/0000-0001-8198-5312; Doros, Attila/0000-0002-6496-9895}
}

@article{MTMT:33862757,
	title = {Gasztroenterológiai-kardiológiai multidiszciplináris konszenzus a hatékony gasztroprotekció szükségességéről antitrombotikus kezelés alkalmazásakor : A Magyar Gasztroenterológiai Társaság és a Magyar Kardiológusok Társaságának közös állásfoglalása},
	url = {https://m2.mtmt.hu/api/publication/33862757},
	author = {Herszényi, László and Aradi, Dániel and Békássy, Szabolcs and Járai, Zoltán and Juhász, Márk and Kiss, Róbert Gábor and Kolossváry, Endre and Nardai, Sándor and Simonyi, Gábor and Szőnyi, Mihály and Tomcsányi, János and Torzsa, Péter and Tulassay, Zsolt and Vincze, Áron and Becker, Dávid},
	doi = {10.26430/CHUNGARICA.2023.53.2.150},
	journal-iso = {CARDIOL HUNG},
	journal = {CARDIOLOGIA HUNGARICA},
	volume = {53},
	unique-id = {33862757},
	issn = {0133-5596},
	abstract = {Az antitrombotikus (thrombocytaaggregáció-gátló – TAG és antikoaguláns) szerek alkalmazása nélkülözhetetlen a szív- és érrendszeri (kardiovaszkuláris – CV) betegségek kezelésében. Az antitrombotikus szerek alkalmazása azonban növeli a tápcsatornai vérzések kockázatát. A megelőzés során a CV és a gasztrointesztinális (GI) kockázati tényezőket egyaránt figyelembe kell venni és hatékony gyomornyálkahártya-védelmet (gasztroprotekciót) kell alkalmazni. A gasztroprotekció alapja a hatékony savszekréció-gátlás. A protonpumpagátló (PPI)-szerek biztosítják a leghatékonyabb gasztroprotekciót. Az antitrombotikus kezelés során az esetek egy részében nem történik hatékony gasztroprotekció, amely a PPI elégtelen alkalmazásával magyarázható. A hatékony gasztroprotekciót illetően jelenleg nem áll rendelkezésre naprakész magyar útmutató vagy ajánlás. A közlemény a legújabb evidenciák tükrében, elismert hazai kardiológus és gasztroenterológus szakértők multidiszciplináris konszenzusa alapján összefoglalja az antitrombotikus kezelés során alkalmazandó gasztroprotekció legfontosabb gyakorlati szempontjait.},
	year = {2023},
	eissn = {1588-0230},
	pages = {150-159},
	orcid-numbers = {Kiss, Róbert Gábor/0000-0003-0514-7530; Simonyi, Gábor/0000-0002-5205-3820; Torzsa, Péter/0000-0002-8148-4961; Tulassay, Zsolt/0000-0003-2452-6640; Vincze, Áron/0000-0003-2217-7686; Becker, Dávid/0000-0002-9025-0323}
}

@article{MTMT:33842885,
	title = {Epeút- és epehólyag-gyulladás: diagnosztikus kritériumok és terápia [Cholangitis and cholecystitis: diagnostic criteria and management]},
	url = {https://m2.mtmt.hu/api/publication/33842885},
	author = {Czakó, László and Gyökeres, Tibor Zoltán and Hritz, István and Madácsy, László and Illés, Dóra and Szepes, Zoltán and Dubravcsik, Zsolt and Péterfi, Zoltán and Nagy, András and Szűcs, Ákos and Vincze, Áron},
	doi = {10.1556/650.2023.32770},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {164},
	unique-id = {33842885},
	issn = {0030-6002},
	abstract = {In developed countries, diseases of the gallbladder and the biliary tract count as some of the most frequent gastrointestinal disorders. The inflammation of the gallbladder/biliary tree is a potentially severe, even lethal condition that requires rapid diagnosis and early multidisciplinary approach to be treated. Although the frequency of these diseases is high, the treatment is not unified in Hungary yet. The aim of the evidence-based recommendation is to clarify the diagnostic criteria and severity grading of these diseases and to highlight the indications and rules of proper application of the numerous available therapeutic interventions. The recent guideline is based on the consensus of the Board members of the Endoscopic Section of the Hungarian Gastroenterology Society in contribution with renown experts of surgery, infectology as well as interventional radiology and it counts as a clear and easy applicable guide during the all-day healthcare practice. Our guidelines are based on Tokyo guidelines established on the basis of the consensus reached in the International Consensus Meeting held in Tokyo which were revised in 2013 (TG13) and in 2018 (TG18). Orv Hetil. 2023; 164(20): 770-787.},
	keywords = {Cholecystectomy; antimicrobial therapy; Acute cholecystitis; CHOLECYSTECTOMIA; antibiotikus kezelés; biliary drainage; Severity grading; acute cholangitis; akut cholangitis; akut cholecystitis; epeúti drenázs; súlyossági osztályozás},
	year = {2023},
	eissn = {1788-6120},
	pages = {770-787},
	orcid-numbers = {Czakó, László/0000-0002-6331-0802; Hritz, István/0000-0002-8763-6006; Szepes, Zoltán/0000-0002-9466-8719; Péterfi, Zoltán/0000-0001-9658-153X; Vincze, Áron/0000-0003-2217-7686}
}

@article{MTMT:33826696,
	title = {Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey},
	url = {https://m2.mtmt.hu/api/publication/33826696},
	author = {Sarlós, Patrícia and Bikar, Alexander and Borbásné Farkas, Kornélia and Resál, Tamás and Szepes, Zoltán and Farkas, Klaudia and Nagy, Ferenc and Vincze, Áron and Miheller, Pál and Molnár, Tamás},
	doi = {10.1080/14712598.2023.2211204},
	journal-iso = {EXPERT OPIN BIOL TH},
	journal = {EXPERT OPINION ON BIOLOGICAL THERAPY},
	volume = {23},
	unique-id = {33826696},
	issn = {1471-2598},
	abstract = {Few data are available on subjective disease control and perception of adverse events (AEs) during switching from original anti-TNF agents to biosimilars.Hungarian patients with inflammatory bowel disease were interviewed after a mandatory non-medical switch from an infliximab (IFX) originator to a biosimilar GP1111 or from an adalimumab (ADA) originator to a biosimilar GP2017. Drug choice was based on patient's and physician's decision. Subjective efficacy was measured using a 10-point scale, and AEs were assessed. Difference in efficacy before and after the switch was compared within and between the drugs.Seventy-three ADA and 106 IFX switching patients were interviewed. Subjective efficacy of IFX biosimilar was rated lower compared to IFX originator (8.72 ± 1.68 vs. 7.77 ± 2.34; p = 0.001). The ADA biosimilar was rated higher than its originator (9.02 ± 1.61 vs. 8.42 ± 1.93; p = 0.017). Patients receiving ADA biosimilar were more satisfied with the new treatment compared to IFX (p = 0.032). The incidence of new AEs was 85% in the ADA and 55% in the IFX group (1.79 vs. 0.93 AEs per patient, respectively, p < 0.001).Subjective efficacy of switching to a biosimilar was proven in case of ADA, while reduced efficacy was experienced with IFX biosimilar. Perception of AEs was high and varied between biosimilars.},
	year = {2023},
	eissn = {1744-7682},
	pages = {827-832},
	orcid-numbers = {Sarlós, Patrícia/0000-0002-5086-9455; Bikar, Alexander/0009-0004-2225-2193; Borbásné Farkas, Kornélia/0000-0002-5349-6527; Resál, Tamás/0000-0002-3842-9094; Szepes, Zoltán/0000-0002-9466-8719; Farkas, Klaudia/0000-0003-0599-182X; Vincze, Áron/0000-0003-2217-7686; Miheller, Pál/0000-0003-3448-4333; Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:33770177,
	title = {Endoscopic diagnosis and treatment in gastric cancer : Current evidence and new perspectives},
	url = {https://m2.mtmt.hu/api/publication/33770177},
	author = {Vincze, Áron},
	doi = {10.3389/fsurg.2023.1122454},
	journal-iso = {FRONT SURG},
	journal = {FRONTIERS IN SURGERY},
	volume = {10},
	unique-id = {33770177},
	abstract = {Gastric cancer is the fifth most common cause of cancer related deaths worldwide. Despite advancement in endoscopic techniques, the majority of the cases are diagnosed at late stage, when the curative treatment options are very limited. The early gastric cancer (EGC) on the other side is potentially curable, and in selected cases endoscopic resection techniques offer similar survival rates then surgical resection. The detection of EGC is endoscopically challenging and requires high quality examination. Recent data show that close to 10% of the gastric cancer cases had a previous negative endoscopy. This highlights the urgent need to improve the quality of the endoscopy services, what can be achieved by increasing the awareness of gastroenterologists and continuously monitoring the key performance indicators of upper gastrointestinal endoscopy. Newer endoscopic imaging techniques are also becoming commonly available to aid the detection of gastric premalignant lesions and EGC. High-definition endoscopy with image enhancement techniques is preferred over white light endoscopy to recognize these lesions, and they are also useful to determine the invasion depth of EGC. The endoscopic optical characterization of lesions is necessary for the selection of proper resection method and decide whether endoscopic resection techniques can be considered. Artificial intelligence systems aid the detection of EGC and can help to determine the depth of invasion. Endoscopic mucosal resection and endoscopic submucosal dissection requires centralized care and tertiary referral centers with appropriate expertise to ensure proper patient selection, high success rate and low adverse event rate. Appropriately scheduled endoscopic surveillance of high-risk patients, premalignant lesions and after resection of EGC is also important in the early detection and successful treatment of gastric cancer.},
	keywords = {OPTICAL CHARACTERIZATION; Endoscopic submucosal dissection; early gastric cancer; gastric premalignant lesions; missed gastric cancer; quality parameters of upper gastrointestinal endoscopy},
	year = {2023},
	eissn = {2296-875X},
	orcid-numbers = {Vincze, Áron/0000-0003-2217-7686}
}